Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

53.87USD
5 May 2016
Change (% chg)

$0.04 (+0.07%)
Prev Close
$53.83
Open
$53.85
Day's High
$54.14
Day's Low
$53.28
Volume
1,224,553
Avg. Vol
1,052,790
52-wk High
$72.31
52-wk Low
$52.64

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $54,821.07
Shares Outstanding(Mil.): 1,022.26
Dividend: 0.34
Yield (%): 2.52

Financials

  TEVA.N Industry Sector
P/E (TTM): 29.58 33.44 41.88
EPS (TTM): 1.82 -- --
ROI: 4.57 13.19 12.66
ROE: 6.32 13.93 13.58
Search Stocks

Teva Pharm finalizing asset sales to clear Allergan deal: source

Teva Pharmaceutical Industries Ltd is finalizing as much as $2 billion in asset sale agreements to win U.S. antitrust clearance for its $40.5 billion acquisition of Allergan Plc's generic drug portfolio, according to a source familiar with the matter.

1:49am IST

Teva Pharm finalizing asset sales to clear Allergan deal -source

May 5 Teva Pharmaceutical Industries Ltd is finalizing as much as $2 billion in asset sale agreements to win U.S. antitrust clearance for its $40.5 billion acquisition of Allergan Plc's generic drug portfolio, according to a source familiar with the matter.

1:42am IST

Biotech stock swoon sparks buyout interest: investor

NEW YORK A brutal start to the year for biotech stocks could pave the way for more deal-making in the sector, with premiums of potentially 50 percent to 100 percent above depressed share prices, according to a top healthcare investor.

04 May 2016

BRIEF-Teva says FDA has approved ProAir RespiClick

* Teva announces fda approval of proair respiclick (albuterol sulfate) inhalation powder for pediatric asthma patients ages 4 to 11

29 Apr 2016

BRIEF-Fitch maintains Teva Pharmaceuticals' ratings on negative watch

* Fitch maintains Teva Pharmaceuticals' ratings on negative watch

21 Apr 2016

BRIEF-Antares says partner Teva first to file for generic version of Lilly's Forteo

* "pen 1" development project with teva pharmaceutical relates to a generic form of forteo marketed by eli lilly

05 Apr 2016

Teva and Takeda name pharma veteran as CEO of Japan joint venture

March 31 Israel's Teva Pharmaceutical Industries Ltd and Japan's Takeda Pharmaceutical Co Ltd named Hiroshi Matsumori on Thursday as the chief executive of their new joint venture in Japan.

01 Apr 2016

BRIEF-Teva Pharmaceutical Industries Ltd announces FDA approval of Cinqair injection

* Teva announces FDA approval of Cinqair (reslizumab) injection

23 Mar 2016

U.S. FDA approves Teva's biotech drug for severe asthma

The U.S. Food and Drug Administration said on Wednesday it had approved Teva Pharmaceutical Industries Ltd's drug to treat asthma in adults who have a history of severe attacks despite taking medication.

23 Mar 2016

UPDATE 1-U.S. FDA approves Teva's biotech drug for severe asthma

March 23 The U.S. Food and Drug Administration said on Wednesday it had approved Teva Pharmaceutical Industries Ltd's drug to treat asthma in adults who have a history of severe attacks despite taking medication.

23 Mar 2016

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF70.65 -0.70
Biogen Inc (BIIB.OQ) $264.62 --

Earnings vs. Estimates

Search Stocks